BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Biorefinery development: Development of various biochemical and
thermochemical routes to fuels, chemicals and materials and perfecting the
dry mill biorefinery process
Cellulose nanofibers: Production of microcrystalline cellulose nanowhiskers
through the utilization of the low-cost AFEX process with surface, interfacial
and mechanical properties in order to make them suitable as reinforcements
and fillers in polymers
PRODUCTS ON MARKET: Contract Services and Pilot-scale Manufacturing: Production of fragrances,
high cell density Escherichia coli fermentation for protein reagents and
protein biologicals, and the scale up of a specialty chemical produced via
fermentation
MDS Pharma Services
Bio-Business Incubator of Michigan: Offers assistance with the regulatory
approval process, interim CEOs, business planning, business plan
development, grant writing, finance and accounting, human resources,
corporate filings, secretarial support, laboratory and technical support, and
access to equipment and offices/laboratory space
The Triad, 2200 Renaissance Blvd., Suite 400
King of Prussia PA 19406-2755, US
Phone: (610) 239-7900; Fax: (610) 239-7111
Web: www.mdsps.com
E-mail: info@mdsps.com
KEY PERSONNEL: David Spaight; President and CEO
Riaz Bandali; VP and GM, Global Early Clinical Research
Robert Beland; VP, Discovery and Preclinical
Robert Butz, Ph.D.; Interim VP and GM, Global Clinical Development
Scott Neilson; VP and GM, Central Laboratories
John Robson; VP and GM, Global Bioanalytical Services
Peter Abram; Sr. VP, Finance
Cam Hicks; Sr. VP, Human Resources and Organizational Development
Jim McClurg, Ph.D.; Sr. VP and CSO
Robert Castellucci; VP, Quality
EMPLOYEES: 3,920 employees
HISTORY: MDS Pharma Services was formed in 1999 from the merging of eight legacy
companies: MDS Harris, MDS Panlabs, MDS Glarif, MDS Analytical
Solutions, MDS Clinical Trial Laboratires, MDS Neo-Pharm, MDS Tricon and
Phoenix International Life Sciences
Sold its Fermentation Technologies business to Panlabs Biologics of Taiwan
(12/05)
FACILITIES: Locations in Johannesburg, South Africa; Beijing, China; Yokohama, Japan;
Malaysia; Singapore; Taipei, Taiwan; Pyrmont, Australia; Mississauga,
Blainville and Saint-Laurent, Canada; Mexico; Phoenix, Ariz.; Irvine, Calif.;
Lincoln, Neb.; Neptune and North Brunswick, N.J.; King of Prussia, Penn.;
Bothell, Wash.; New Orleans, La.; Buenos Aries, Argentina; Santiago, Chile;
Lima, Peru; Brussels, Belgium; Czech Republic; France; Germany;
Hungary, Italy; Poland; Romania; Madrid, Spain; Lund, Sweden;
Switzerland; Kiev, Ukraine; and the U.K.
STOCK-FINANCIAL HISTORY: Privately held by parent
SUBSIDIARY OF: MDS International Inc. (see separate entry)
BUSINESS STRATEGY: To be the premier provider of innovative drug discovery and development
solutions by offering our expertise in the areas of lead optimization, pre-IND
research, pharmaceutical and biopharmaceutical development, early clinical
research (bioequivalence, phases I-IIa), bioanalysis, global clinical
development (phases IIb-IV) and central lab
Copyright ©2006 AHC Media ® 234